Lysogene announced the nomination of Philippe Mendels-Flandre as Chief Operating Officer and a member of the Board of Directors. Mendels-Flandre’s arrival strengthens Lysogene’s Board of Directors in order to accompany its new strategic growth goals. As such, he will supervise all financial activities of the company as well as partnerships and Business Development initiatives. Mendels-Flandre will be a member of the Executive Committee. Previously, Mendels-Flandre was Shire’s pharmaceutical group specialized in rare diseases - EAMEA General Manager, which he joined in 2000 when the company was still called Baxter, then Baxalta.